Evidence map›Paper›PMID 36694063›Full record

ArticleInternational journal of hematology2023

Dasatinib for chronic myelomonocytic leukemia with ZMIZ1-ABL1 fusion gene: a case report.

Heng Liu, Hai Bai, Shuting Zhang, Xiaochen Zhao, Dongfeng Mao, Rui Xi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Heng LiuDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China.
Hai BaiDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China.
Shuting ZhangDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China.
Xiaochen ZhaoDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China.
Dongfeng MaoDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China.
Rui XiDepartment of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, 333 South Binhe Middle Road, Lanzhou, 730050, China. xirui36@qq.com.
Chinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The fusion gene ZMIZ1-ABL1 is rare, with only one known case reported in lymphatic system malignancies, and none reported in a myeloid tumor. Here, we report the case of a patient with chronic myelomonocytic leukemia with the ZMIZ1-ABL1 fusion gene. Elevated leukocytes and splenomegaly were the main manifestations. Remission was achieved with the second-generation tyrosine kinase inhibitor (TKI) dasatinib, and the response has been sustained for 10 months. The treatment results in this case suggest that dasatinib is effective in treating ZMIZ1-ABL1 fusion gene-positive disease.

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myelomonocytic, ChronicDasatinibDrug Resistance, NeoplasmFusion Proteins, bcr-ablHumansProtein Kinase InhibitorsTranscription FactorsDasatinibFusion Proteins, bcr-ablProtein Kinase InhibitorsTranscription FactorsZMIZ1 protein, humanChronic myelomonocytic leukemiaMyelodysplastic/myeloproliferative neoplasmTyrosine kinase inhibitorsZMIZ1-ABL1

Identifiers

PMID36694063
OpenAlexW4317840163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.